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204 The Journal of Thoracic and CardioBackground: There are few data in the literature regarding the utility of open lung
biopsy for the assessment of graft dysfunction after pediatric lung transplantation.
The aim of this study is to review our experience with diagnostic open lung biopsy
in lung transplant recipients in a children’s hospital.
Methods: Records of lung transplant recipients from January 1990 through Decem-
ber 2002 were reviewed to identify the indications, outcomes, and complications of
open lung biopsy.
Results: Two hundred twenty-four patients (mean age, 9.9 6.2 years; median age,
11 years; age range, 0.01-19.6 years) underwent 249 lung transplantations: 231
bilateral, 8 single, and 10 heart-lung transplantations. Mean follow-up was 3.4 years.
One hundred three open lung biopsies were performed in 89 (40% of all recipients)
patients. Thirteen recipients underwent open lung biopsy twice, and 1 recipient had
3 open lung biopsies. The indications for open lung biopsy were suspicion of
bronchiolitis obliterans (n  70), posttransplantation lymphoproliferative disorder
(n  15), infection (n  8), and unexplained respiratory failure (n  10). A new
diagnosis was made in 49 biopsies (48%), 50 biopsies (49%) confirmed the preop-
erative clinical diagnosis, and 4 biopsies (3%) were nondiagnostic. Bronchiolitis
obliterans was confirmed in 40 (57%) of 70 open lung biopsies, posttransplantation
lymphoproliferative disorder was confirmed in 4 (27%) of 15 open lung biopsies,
and infection was confirmed in 6 (75%) of 8 open lung biopsies. A change in therapy
occurred in 69% of the cases as a result of the diagnosis made from open lung
biopsy. There was no mortality as a direct result of open lung biopsy. Eleven major
complications and 22 minor complications occurred in 103 procedures.
Conclusion: Open lung biopsy can be performed safely, and established or con-
firmed a diagnosis in 97% of the cases. A change in therapy occurred in 69% of the
cases as a result of the diagnosis made from open lung biopsy. In our experience
open lung biopsy appears to be a useful tool.
Open lung biopsy (OLB) has been used as a diagnostic tool in the evaluationof pulmonary diseases in lung transplant recipients when other investiga-tions have been nondiagnostic. However, there are few data in the literature
regarding the utility of OLB in lung transplant recipients. The purpose of this report
is to review our experience with the use of diagnostic OLB in lung transplant
recipients in a single children’s hospital.
Patients and Methods
Patients
Between January 1990 and December 2002, 224 patients underwent 249 lung transplantations
at the St Louis Children’s Hospital. Two hundred thirty-one were bilateral sequential lung
transplantations (BLTs), 8 were single-lung transplantations, and 10 were heart-lung trans-
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TXplantations (HLTs). The median age at the time of transplantation
was 11 years, and the mean age was 9.9  6.2 years (age range,
0.01-19.6 years). Indications, outcomes, and complications of
OLB were obtained by means of a retrospective review of infor-
mation prospectively collected in a computer database and from
medical records. This study was reviewed and approved by the
Washington University School of Medicine Human Studies
Committee.
Operative Technique
Transplantation. The techniques have been well described else-
where.1,2 BLT was performed through a bilateral anterolateral trans-
sternal (clamshell) thoracotomy incision through the fourth intercostal
space. Single-lung transplantation was performed through an antero-
lateral thoracotomy extended across the sternum into the contralat-
eral chest. HLT was performed through a median sternotomy. The
majority of the operations were performed with the use of cardio-
pulmonary bypass because the airways in children are too small to
safely accommodate the double-lumen endotracheal tubes that are
necessary for single-lung ventilation.
OLB. OLB was performed after achievement of general anes-
thesia through a minianterolateral thoracotomy. The side (right or
left) chosen in patients who had BLT or HLT is guided by the
presence and severity of radiologic abnormalities. A lung speci-
men is removed and sent off for microbiologic and histologic
analysis. Biopsies from 2 different locations were performed if 2
abnormal areas with clear differences were seen in the lung on
preoperative imaging or during intraoperative inspection. The
wound is routinely closed in layers. A chest tube is normally not
inserted unless there is evidence of significant air leakage from the
biopsy sites or from lung areas where adhesions have been divided
during thoracotomy and exposure.
Transplant Management
Routine postoperative management has been described previously.3
All patients received triple-drug immunosuppression (typically
prednisone, cyclosporine [INN: ciclosporin], and azathioprine) and
had routine scheduled surveillance to guide the maintenance of
immunosuppressive therapy. Surveillance included pulmonary func-
tion measurements with standard techniques4,5 and flexible bronchos-
copy with biopsies and bronchoalveolar lavage (BAL).6,7 These were
performed at 2 weeks, 1 month, 2 months, 3 months, and every 3
months thereafter, as well as at any time that a change in clinical
status occurred for which rejection was a plausible explana-
Abbreviations and Acronyms
BAL  bronchoalveolar lavage
BLT  bilateral sequential lung transplantation
BO  bronchiolitis obliterans
HLT  heart-lung transplantation
OLB  open lung biopsy
PTLD posttransplantation lymphoproliferative
disorder
TBB  transbronchial biopsytion.3,6,7 OLB was performed when a patient had a clinical suspi-
The Journal of Thoracicion of pulmonary disease that was not confirmed by the above-
mentioned investigations. These included patients in 4 groups: (1)
patients with a clinical suspicion of bronchiolitis obliterans (BO)
on the basis of a decrease in pulmonary function measurements
without a clear diagnosis or explanation; (2) patients with a clinical
suspicion of posttransplantation lymphoproliferative disorder
(PTLD) on the basis of detectable lung nodules on chest radiog-
raphy, computed tomography, or both; (3) patients with a clinical
suspicion of infection, including clinical features consistent with a
pulmonary infection and infiltrates seen on chest radiographs, but
without a confirmatory diagnosis on the basis of the above-
mentioned investigations; and (4) patients with unexplained
respiratory failure associated with sudden clinical deterioration
without an obvious cause and not fitting into groups 1 to 3.
Statistics
Descriptive statistics were used to describe the patients’ charac-
teristics and outcomes. Normally distributed continuous data are
expressed as means  standard deviations throughout. Medians
with ranges are used when continuous data are not normally
distributed. Categoric data are expressed as counts and propor-
tions. The 2 or Fisher exact test was used to analyze the categoric
data. Kaplan-Meier (product-limit) graphs were used to demon-
strate survival over time and freedom from BO. Survival and
event-free survival comparisons between groups of patients were
completed by using the Mantel-Haenszel log-rank test. All data
analysis was performed with SPSS software (SPSS 11.0 for Win-
dows; SPSS Inc, Chicago, Ill).
Results
One hundred three OLBs were performed in 89 patients (47
male patients; mean age, 12.3  6.1 years) during a mean
follow-up of 3.4 years. Thirteen recipients underwent OLB
twice, and 1 recipient had 3 OLBs. The median period
between lung transplantation and OLB was 14.9 months
(range, 1 day to 8.13 years; mean, 25.8 25.6 months). The
indications and results of OLB are shown in Table 1. A new
diagnosis was made in 48% of the cases. The new diagnoses
made in the 27 (39%) patients with a clinical suspicion of
BO were infective pneumonia (n  8), pneumonitis (n 
13), BO with organizing pneumonia (n  4), hemorrhagic
infarction (n  1), and Kaposi sarcoma (n  1). The new
diagnoses made in the 10 (67%) patients with clinical suspi-
cion of PTLD were BO (n  5), infective pneumonia (n 
2), pneumonitis (n  2), and thrombotic emboli (n  1). The
2 (25%) new diagnoses in patients with clinical suspicion of
infection were BO and pneumonitis. The diagnoses found after
OLB for unexplained respiratory failure were BO and infective
pneumonia (n  2), infective pneumonia only (n  1), pneu-
monitis (n 4), diffuse alveolar damage (n 2), and BO with
organizing pneumonia (n  1).
Of the 103 OLBs performed, a change in therapy oc-
curred in 69% of the cases (Table 2). The majority of
patients with a new diagnosis after OLB had a change in
therapy. Among the 40 patients with a confirmed diagnosis
of BO, 28 had a change of therapy in the form of either a
c and Cardiovascular Surgery ● Volume 131, Number 1 205
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or removal of unwarranted concomitant therapy, such as
antibacterial or antiviral medications. Among the 4 patients
with confirmed PTLD, all patients had a change in therapy
in the form of commencement of chemotherapy or a de-
crease in immunosuppressive therapy. Among the 6 patients
with a confirmed diagnosis of infection, 5 patients had a
change in therapy in the form of either a change in the type
or dose of the antibacterial or antiviral medications. Six of
the patients with unexplained respiratory failure had a
change in management. No change in therapy was instituted
among the patients with a nondiagnostic result. Overall, a
change in therapy occurred after OLB in 66%, 80%, 88%,
and 60% of the cases with a preoperative suspicion of BO,
PTLD, infection, and unexplained respiratory failure, re-
spectively. For those undergoing OLB for clinical suspicion
of BO, there was no survival difference between patients
who had a confirmed diagnosis and those who had a new
diagnosis after OLB for clinical suspicion of BO (Figure 1).
There was no mortality as a direct result of OLB. Eleven
major and 22 minor complications occurred as a result of
OLB procedures (Table 3).
Discussion
As the success of lung transplantation increased over the
last 2 decades, an increase in the number and spectrum of
pulmonary complications has also been recognized.8 The
care of lung transplant recipients presents many diagnostic
and therapeutic challenges. Long-term survivors of lung
transplantation continue to be plagued by a high rate of
TABLE 1. Indications and results of open lung biopsies
Indications, n  103 (clinical suspicion) Confirmed dia
Bronchiolitis obliterans, n  70 40 (57
PTLD, n  15 4 (27
Infection, n  8 6 (75
Unexplained respiratory failure, n  10 0
Overall, n  103 50 (49
PTLD, Posttransplantation lymphoproliferative disorder.
TABLE 2. A change in therapy
Indications (clinical suspicion) Confirmed diagnosis
Bronchiolitis obliterans, n  70 28/40 (70%)
PTLD, n  15 4/4 (100%)
Infection, n  8 5/6 (83%)
Unexplained respiratory failure, n  10 0/0PTLD, Posttransplantation lymphoproliferative disorder.
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The most common difficulty in the care of these patients is
differentiating not only between these 2 most common
disease classes, rejection or infection, but also among the
different types of disease within each class: acute or chronic
rejection and bacterial, viral, fungal, mycobacterial, or par-
asitic infection. These complications often require a quick
and safe procedure to establish a diagnosis. History, phys-
ical examination, pulmonary function tests, and chest radio-
graphs are inadequate in differentiating among the many
pulmonary problems that can occur in transplant recipients.
Although spirometry has a sensitivity of 75% to 86% in
detecting lung rejection or infection, it cannot differentiate
between these 2 broad disease categories.9 Other groups
have reported even poorer sensitivities on spirometric tests,
ranging as low as 31%.10 Chest radiographs are also non-
specific and generally unhelpful in distinguishing among
various disease processes.
The preferred route for investigation of pulmonary com-
plication in lung transplant recipients is bronchoscopy.
Transbronchial biopsy (TBB), used in the surveillance of
these patients or in the case of acute clinical deterioration,
has been shown to be useful in the detection of occult
rejection or infection, especially when combined with
BAL.11-13 However, clinical settings arise in which symp-
toms and noninvasive studies, pulmonary function tests, and
chest radiographs suggest lung pathology but bronchoscopy
with TBB and BAL fails to establish a diagnosis. In addi-
tion, rapid deterioration of a patient’s condition might de-
mand a faster mode of investigation to establish a diagnosis
Results
s (%) New diagnosis (%) Nondiagnostic (%)
27 (39%) 3 (4%)
10 (67%) 1 (4%)
2 (25%) 0
10 (100%) 0
49 (48%) 4 (3%)
Change in therapy
New diagnosis Nondiagnostic Overall
18/27 (67%) 0/3 (0%) 46/70 (66%)
8/10 (80%) 0/1 (0%) 12/15 (80%)
2/2 (100%) 0/0 7/8 (88%)
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procedures. In these cases OLB might be necessary.
OLB, although clearly more invasive than most diagnos-
tic modalities, can provide useful information in a dete-
riorating patient because more tissue is provided to the
pathologist. Conversely, TBB specimens are small frag-
ments of randomly sampled lung and often are not truly
representative of the entire allograft. We have routinely
used OLB when all other investigations have been nondi-
agnostic and have decided to review the OLB results in our
children’s hospital program over a 13-year period.
There are few data evaluating the usefulness of OLB in
lung transplant recipients.14-18 Paradis and coauthors14 re-
ported their experience with 10 OLBs that were performed
after TBB in which the clinical situation was uncertain. The
OLB revealed new information in 3 instances. Magee and
associates15 reported their experience of OLBs performed
through thoracoscopy in 5 lung transplant recipients after
TBB had failed to establish a diagnosis. They found that this
approach was effective with little morbidity. The Loyola
group reported their series of 18 OLBs in 16 transplant
recipients and revealed a variety of diagnoses.16 However,
they did not report whether the biopsies resulted in treat-
ment changes, although the information obtained would
likely result in therapy interventions in the majority of the
cases.
Chaparro and colleagues18 reported the experience of the
Toronto Lung Transplant Program in which 32 of 144 recipi-
ents underwent 38 OLBs over a 10-year period. Eleven OLBs
were performed early (45 days postoperative), with persis-
tent parenchymal infiltrates as the indication. The remaining
27 OLBs were performed late (45 days). Progressive
radiologic disease with clinical findings or progressive loss
of pulmonary function was the predominant indication in
Figure 1. Kaplan-Meier survival in patients with clinical suspicion
of bronchiolitis obliterans (BO), comparing patients with open lung
biopsy–confirmed BO versus those with other diagnoses.the late group. The group found that a new diagnosis that
The Journal of Thoracichanged therapy was made in only 1 of 11 early OLBs but
in 8 of 27 late OLBs. Eleven of the cases confirmed the
suspected diagnosis, but treatment did not change as a result
of the biopsy findings. An additional 2 biopsies suggested a
diagnosis but likewise did not affect therapy. The nonspe-
cific OLB findings were 42%, and these did not result in
treatment changes. They concluded that OLB is of little
value in the perioperative period but yields useful informa-
tion in approximately 30% of patients when performed late.
Weill and coworkers17 from the University of Alabama
reported their experience of 48 OLBs performed in 42 of
202 patients who underwent lung transplantation between
1989 and 2000. A new clinically unsuspected diagnosis was
made in 29% of all OLBs, and all of these resulted in
therapy changes. Sixty-seven percent of all OLBs confirmed
their clinical suspicions, and new therapy was initiated in 30
of these patients. Their nondiagnostic yield was 4% and did
not result in any therapy change. Complications occurred in
only 3 patients, all of whom had air leak for more than 7
days. The study found that the data obtained from OLBs
was uniformly distributed according to time after transplan-
tation in terms of new and confirmatory diagnosis that
resulted in therapy changes, which is in contrast to the
findings by Chaparro and colleagues.18 Weill and co-
workers17 concluded that OLB was useful and should be
considered when the diagnosis is uncertain in clinically
deteriorating patients.
In our experience a new diagnosis was found in 48% of
the cases after OLB, and the majority of these patients had
a change in therapy. The results of OLB further confirmed
a suspected diagnosis in 49% of the cases. This confirma-
tory information has been found to be useful because al-
TABLE 3. Complications after 103 open lung biopsies
Major 11 (11%)
Respiratory failure requiring postoperative
mechanical ventilation in patients who were
not receiving preoperative mechanical
ventilation 6
Acute renal failure 2
Postoperative bleeding requiring re-exploration 2
Postoperative oxygen dependence in patient who
was not receiving preoperative oxygen 1
Minor 22 (21%)
Postoperative pneumothorax or air leakage
requiring chest tube insertion 12
Representation after discharge for evaluation of
postoperative pain 6
Hypoventilation requiring treatment 1
Superficial wound infection 1
Acute urinary retention requiring indwelling
urinary catheter insertion 1though it might not result in a better outcome, it confirms
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“shotgun,” expensive, and nonindicated presumptive ther-
apy because of uncertainty about the diagnosis. Toxic med-
ications can be avoided that might have been used had
empiric treatment been needlessly initiated. Most, if not all,
of the medications used to treat acute and chronic rejections,
as well as infections, are associated with significant side
effects. Furthermore, the enhanced immunosuppressive reg-
imens used to treat persistent acute rejection and chronic
rejection increase the risk to the patient for opportunistic
infections and PTLD, which can lead to significant morbid-
ity and mortality. It is possible to avoid these regimens if an
exact diagnosis can be made. The confirmatory information
after the OLB in our patients resulted in a change of man-
agement in the majority of these patients. However, it is not
possible to determine whether the same therapies would
have been eventually given even without OLB. In our
experience the nondiagnostic yield of OLB was low at 3%.
Another limitation of this study is that it is a retrospective
review and has limitations inherent to all retrospective stud-
ies. The major complication rate of 11% after OLB among
our patients was comparable with the rate of 12% reported
by Chaparro and colleagues.18 No patient died as a direct
result of OLB among our study population.
In summary, we have found that despite the availability
of various useful investigative tools, such as radiology,
pulmonary function studies, bronchoscopy, TBB, and BAL,
it was not possible to diagnose pulmonary processes in 40%
of our recipients. Although we will continue to use TBB and
BAL as the primary means for diagnosis of pulmonary
complications in lung transplant recipients, when these ap-
proaches fail, we find that diagnostic OLB plays an impor-
tant role in establishing diagnosis and guiding therapy.
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